Skip to content
Screener

Gilead Sciences GILD Total Liabilities

Total Liabilities at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$65.32B-15.4%
Incyte logo
IncyteINCY
$1.53B-7.4%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$1.52B+69.5%
Precigen logo
PrecigenPGEN
$118.39M+42.6%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$179.49M-14.1%
Celcuity logo
CelcuityCELC
$356.64M+171%

Other financials

Income statement

See full
Revenue$7.8B+10.2%
Gross profit$6.2B+11.5%
Operating income-$10.4B-520%
Net income-$10.5B-636%
EPS (diluted)-$8.45-642%

Balance sheet

See full
Cash & equivalents$3.2B-38.2%
Total debt$26.2B+5.2%
Total equity$11.8B-39.9%
Total assets$49.4B-11.4%

Cash flow

See full
Operating cash flow$3.6B+332%
CapEx$140.0M+30.8%
Free cash flow$3.4B+377%

Valuation

See full
Market cap$163.59B+19.3%
Enterprise value$186.66B+18.9%
P/S5.4×+0.6×

Profitability

See full
Gross margin79.6%+1.1pp
Operating margin-8.2%-36.1pp
Net margin-10.6%-32.5pp
FCF margin42.5%+10.0pp

Returns & leverage

See full
Return on equity-20.6%-53.8pp
Debt / equity2.2×+1.0×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Gilead Sciences in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesFairValueDisclosure.

The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000882095-26-000031

FAQ

What is Gilead Sciences's total liabilities?
Gilead Sciences (GILD) reported total liabilities of $535M in Q2 2026.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about Gilead Sciences's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude